GE renews supply deal with Columbia
GE Medical Systems last month renewed its agreement to supply Columbia/HCA Healthcare with medical imaging equipment and services. The multi-year deal is estimated at approximately $1.5 billion. Waukesha, WI-based GE will provide all of Columbia’s
GE Medical Systems last month renewed its agreement to supply Columbia/HCA Healthcare with medical imaging equipment and services. The multi-year deal is estimated at approximately $1.5 billion. Waukesha, WI-based GE will provide all of Columbias U.S. facilities with products for such imaging modalities as CT, MR, nuclear medicine, x-ray, mammography, and ultrasound, and for patient monitoring systems, as well as maintenance and servicing of these systems. GE will also offer Columbia training and consulting services.
The agreement continues the relationship GE started with Columbia in 1995, when it signed a five-year contract to provide comprehensive equipment maintenance and asset management services to Columbia/HCA hospitals (SCAN 3/15/95).
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
